Mumbai, Maharashtra, India, April 2026 – C S Muralidharan has been appointed as Chief Financial Officer at Encube Ethicals, bringing decades of global finance leadership experience to strengthen the company’s strategic and financial capabilities.
In his new role, Muralidharan will be responsible for leading financial strategy, governance, compliance, and business growth initiatives, supporting Encube’s continued expansion in the global pharmaceutical and contract manufacturing space.
Prior to joining Encube Ethicals, Muralidharan served as Group Chief Financial Officer at Sun Pharmaceutical Industries Limited, where he led global finance operations including M&A, investor relations, ESG, governance, and finance transformation across the group.
Earlier, he was Group Chief Financial Officer at Teva Pharmaceuticals, where he managed financial operations across multiple legal entities in India and APAC, along with responsibilities spanning compliance, reporting, and manufacturing finance performance.
He also held leadership roles at Allergan, including Country Head and Chief Financial Officer, where he led large-scale operations, R&D integration, supply chain optimization, and global finance transformation initiatives.
Earlier in his career, Muralidharan served as Chief Financial Officer at Mylan Laboratories Limited, where he played a key role in major M&A transactions, investor relations, and corporate governance, contributing to significant business growth and value creation.
His professional journey also includes senior finance leadership roles at Lupin Limited, Ranbaxy, and Indian Oil Corporation Limited, building deep expertise across strategic finance, capital structuring, compliance, and operational excellence.
With over three decades of experience, Muralidharan brings a strong combination of strategic vision, financial discipline, and global leadership, making him a key addition to Encube’s leadership team.
Encube Ethicals is an integrated pharmaceutical company specializing in topical formulations, with over 23 years of experience in contract development and manufacturing (CDMO).
The company operates the world’s largest single-site topical manufacturing facility in Goa, catering to both prescription and OTC pharmaceuticals as well as cosmetic semisolid dosage forms. Its R&D center in Mumbai houses 150+ scientists, focused on developing innovative topical formulations for global markets.
Encube continues to strengthen its position as a global leader in dermatology and topical drug delivery, driven by innovation, scale, and quality.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
